D. boral capital served as co-manager to immunitybio, inc. (nasdaq: ibrx) in connection with its $100.0 million underwritten public offering

Culver city, calif., dec. 12, 2024 (globe newswire) -- immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. immunitybio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. all of the shares were sold by immunitybio. before deducting the underwriting discount and offering expenses payable by immunitybio, immunitybio expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. the offering is expected to close on or about december 12, 2024 subject to satisfaction of customary closing conditions.
IBRX Ratings Summary
IBRX Quant Ranking